POSSIBLE INVOLVEMENT OF OATP2B1 IN GASTROINTESTINAL TOXICITY INDUCED BY SN-38, THE ACTIVE METABOLITE OF ANTICANCER IRINOTECAN

被引：0
|
作者：
Fujita, Daichi [1 ]
Saito, Yoshimasa [2 ]
Nakanishi, Takeo [1 ]
Tamai, Ikumi [1 ]
机构：
[1] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Fac Pharmaceut Sci, Dept Membrane Transport & Biopharmaceut, Kanazawa, Ishikawa, Japan
[2] Natl Canc Ctr, Dept Pharm, Tokyo, Japan
来源：
DRUG METABOLISM REVIEWS | 2015年 / 47卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P522
引用
收藏
页码：287 / 288
页数：2
相关论文
共 50 条
  • [1] Organic Anion Transporting Polypeptide (OATP)2B1 Contributes to Gastrointestinal Toxicity of Anticancer Drug SN-38, Active Metabolite of Irinotecan Hydrochloride
    Fujita, Daichi
    Saito, Yoshimasa
    Nakanishi, Takeo
    Tamai, Ikumi
    DRUG METABOLISM AND DISPOSITION, 2016, 44 (01) : 1 - 7
  • [2] OATP1B1-MEDIATED HEPATIC UPTAKE OF SN-38, AN ACTIVE METABOLITE OF IRINOTECAN, AND ITS INHIBITION BY UREMIC TOXINS IN HUMANS
    Fujita, K.
    Sugiura, T.
    Okumura, H.
    Umeda, S.
    Nakamichi, N.
    Sasaki, Y.
    Kato, Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S32 - S32
  • [3] Development of ELISAs for irinotecan and its active metabolite SN-38
    Saita, T
    Fujito, H
    Mori, M
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2000, 23 (08) : 911 - 916
  • [4] CHARACTERIZATION OF HEPATIC UPTAKE MECHANISM FOR SN-38, AN ACTIVE METABOLITE OF THE ANTICANCER AGENT IRINOTECAN IN HUMANS
    Kato, Yukio
    DRUG METABOLISM REVIEWS, 2012, 44 : 95 - 96
  • [5] UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan
    Ando, Y
    Saka, H
    Asai, G
    Sugiura, S
    Shimokata, K
    Kamataki, T
    ANNALS OF ONCOLOGY, 1998, 9 (08) : 845 - 847
  • [6] Panipenem Does Not Alter the Pharmacokinetics of the Active Metabolite of Irinotecan SN-38 and Inactive Metabolite SN-38 Glucuronide (SN-38G) in Rats
    Kato, Ayako
    Ueyama, Jun
    Abe, Fumie
    Hotta, Kazuo
    Tsukiyama, Ikuto
    Oshima, Taeyuki
    Kondo, Fumio
    Saito, Hiroko
    Hasegawa, Takaaki
    ANTICANCER RESEARCH, 2011, 31 (09) : 2915 - 2922
  • [7] Effect of Tacrolimus on the Pharmacokinetics and Glucuronidation of SN-38, an Active Metabolite of Irinotecan
    Tanaka, Yoshiteru
    Katoh, Miki
    Fujioka, Miho
    Onishi, Katsuhiro
    Sakakibara, Yukiko
    Hasegawa, Takaaki
    Nadai, Masayuki
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2013, 133 (04): : 463 - 471
  • [8] Glucuronidation of SN-38, the active metabolite of irinotecan, by human hepatic microsomes
    Haaz, MC
    Rivory, L
    Jantet, S
    Ratanasavanh, D
    Robert, J
    PHARMACOLOGY & TOXICOLOGY, 1997, 80 (02): : 91 - 96
  • [9] Passage of irinotecan and its active metabolite, SN-38, into human milk
    Nakagawa, J.
    Terui, K.
    Hosoi, K.
    Ueno, K.
    Yokoyama, Y.
    Hayakari, M.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2016, 41 (05) : 579 - 582
  • [10] Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38
    Iwase, Mariko
    Fujita, Ken-ichi
    Nishimura, Yuki
    Seba, Natsumi
    Masuo, Yusuke
    Ishida, Hiroo
    Kato, Yukio
    Kiuchi, Yuji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (05) : 993 - 998
12345